Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G., Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 361 - 369 [articolo]
De Giglio A.; Orlando V.; Andrini E.; Ricciuti B.; Lamberti G.; Chiari R., Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities, «TUMORI», 2022, not reported, pp. 3008916211069412 - 3008916211069418 [articolo]
Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Lobefaro R.; Lopez-Castro R.; Bosch-Barrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar-Nana F.; Ponce S.; Dal Maso A.; Spotti M.; Mielgo-Rubio X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Planchard D.; Mezquita L., Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations, «EUROPEAN JOURNAL OF CANCER», 2022, 167, pp. 142 - 148 [articolo]
De Giglio A.; Di Federico A.; Metro G., Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer, «TRANSLATIONAL LUNG CANCER RESEARCH», 2022, 11, pp. 1734 - 1738 [articolo]
Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Francesca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea, Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes, «CANCERS», 2022, 14, Article number: 3472, pp. 1 - 15 [articolo]Open Access
Ricciuti B.; Mira A.; Andrini E.; Scaparone P.; Michelina S.V.; Pecci F.; Cantini L.; De Giglio A.; Lamberti G.; Ambrogio C.; Metro G., How to manage KRAS G12C-mutated advanced non-small-cell lung cancer, «DRUGS IN CONTEXT», 2022, 11, pp. 1 - 11 [articolo]
Andrini E.; Di Federico A.; Sisi M.; Rosellini M.; Palladini A.; Lamberti G.; De Giglio A.; Gelsomino F., Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies, «IMMUNOTHERAPY», 2022, 14, pp. 1329 - 1340 [articolo]
Di Federico A.; Mosca M.; Pagani R.; Carloni R.; Frega G.; De Giglio A.; Rizzo A.; Ricci D.; Tavolari S.; Di Marco M.; Palloni A.; Brandi G., Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, «CANCERS», 2022, 14, Article number: 2429, pp. 1 - 14 [articolo]Open Access
Alessandro Di Federico, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, Dalia Ricci, Simona Tavolari, Mariacristina Di Marco, Andrea Palloni, Giovanni Brandi., Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes, «CANCERS», 2022, 14, Article number: 2429, pp. 1 - 14 [articolo]Open Access
De Giglio, Andrea; Aprile, Marta; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Ardizzoni, Andrea, Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC), «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2022, 23, pp. 10292 - 10299 [articolo]Open Access
De Giglio, Andrea; Grandinetti, Valeria; Aprile, Marta; Borelli, Greta; Campus, Anita; Croci Chiocchini, Anna Laura; Busutti, Marco; Vischini, Gisella; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea; La Manna, Gaetano; Gelsomino, Francesco, Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience, «LUNG CANCER», 2022, 174, pp. 91 - 96 [articolo]
Sisi, Monia; Fusaroli, Michele; De Giglio, Andrea; Facchinetti, Francesco; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco, Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System, «TARGETED ONCOLOGY», 2022, 17, pp. 43 - 51 [articolo]Open Access
De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea, The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy, «CANCERS», 2022, 14, pp. 5845 - 5851 [articolo]Open Access
Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G., An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances, «PHARMACEUTICALS», 2021, 14, Article number: 316, pp. 316 - 339 [articolo]Open Access
Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R.; Pirro M., Antibody–drug conjugates for lung cancer in the era of personalized oncology, «SEMINARS IN CANCER BIOLOGY», 2021, 69, pp. 268 - 278 [articolo]
